NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 D-cycloserine and Lurasidone, an oral, fixed dosed combination of D-cycloserine/lurasidone that earned food and drug administration-designated as breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 ketamine, which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior ASIB. The company has a partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

NRX Pharmaceuticals Inc.

The Vanguard Total Stock Market ETF ($VTI) tracks the broader U.S. stock market. The fund attracted strong investor interest recently, with about $...

VTI Sees $1B Inflows as Vanguard ETF Gains Momentum — 3/19/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, was down 1.1% at market open on Thursday. Investor sentimen...

Why Is the VTI ETF Down Today? Daily Snapshot – 3/12/26

Choosing between a mutual fund and an ETF can be tricky, even when both track the same index. Vanguard Total Stock Market Index Fund Admiral Shares...

Mutual Fund vs. ETF? Should You Buy VTSAX or VTI in 2026?

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.26% in pre-market hours on Tuesday. Overall, VTI ...

Market Cap	$73.74M	P/E Ratio	17.37
52W High	$3.84	52W Low	$1.58
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	30.0%
Overall Score	47	Value Score	40
Quality Score	--	Technical Score	54

EPS Current Est	$0.13	EPS Next Est	$1.23
EPS Growth Est	+846.2%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRXP	$2.26	+1.26%	629.50K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NRXP	$2.26	+1.3%	629.50K
3
4
5
6

NRXP

NRXP

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get NRX Pharmaceuticals Inc. Data in Excel

Get NRX Pharmaceuticals Inc. Data in Excel